Terms: = Prostate cancer AND TGFBR2, AAT3, 7048, ENSG00000163513, P37173, TGFbeta-RII, RIIC, TAAD2, FAA3, TGFR-2, MFS2, HNPCC6
28 results:
1. Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
Tombal B; Sternberg CN; Hussain M; Ganguli A; Li Y; Sandin R; Bhadauria H; Oh M; Saad F
ESMO Open; 2022 Jun; 7(3):100510. PubMed ID: 35714477
[TBL] [Abstract] [Full Text] [Related]
2. Downregulation of miR-485-3p promotes proliferation, migration and invasion in prostate cancer through activation of TGF-β signaling.
Chen D; Fan J; Li X; Jiao Z; Tang G; Guo X; Chen H; Wang J; Men T
Histol Histopathol; 2022 May; 37(5):423-430. PubMed ID: 34958117
[TBL] [Abstract] [Full Text] [Related]
3. Enzalutamide-induced and PTH1R-mediated tgfbr2 degradation in osteoblasts confers resistance in prostate cancer bone metastases.
Su S; Cao J; Meng X; Liu R; Vander Ark A; Woodford E; Zhang R; Stiver I; Zhang X; Madaj ZB; Bowman MJ; Wu Y; Xu HE; Chen B; Yu H; Li X
Cancer Lett; 2022 Jan; 525():170-178. PubMed ID: 34752846
[TBL] [Abstract] [Full Text] [Related]
4. TGFβ signaling limits lineage plasticity in prostate cancer.
Hao Y; Bjerke GA; Pietrzak K; Melhuish TA; Han Y; Turner SD; Frierson HF; Wotton D
PLoS Genet; 2018 May; 14(5):e1007409. PubMed ID: 29782499
[TBL] [Abstract] [Full Text] [Related]
5. Attenuation of tgfbr2 expression and tumour progression in prostate cancer involve diverse hypoxia-regulated pathways.
Zhou H; Wu G; Ma X; Xiao J; Yu G; Yang C; Xu N; Zhang B; Zhou J; Ye Z; Wang Z
J Exp Clin Cancer Res; 2018 Apr; 37(1):89. PubMed ID: 29699590
[TBL] [Abstract] [Full Text] [Related]
6. Loss of TGF-β signaling in osteoblasts increases basic-FGF and promotes prostate cancer bone metastasis.
Meng X; Vander Ark A; Daft P; Woodford E; Wang J; Madaj Z; Li X
Cancer Lett; 2018 Apr; 418():109-118. PubMed ID: 29337106
[TBL] [Abstract] [Full Text] [Related]
7. An androgen-regulated miR-2909 modulates TGFβ signalling through AR/miR-2909 axis in prostate cancer.
Ayub SG; Kaul D; Ayub T
Gene; 2017 Oct; 631():1-9. PubMed ID: 28754634
[TBL] [Abstract] [Full Text] [Related]
8. Comprehensive gene expression analysis reveals multiple signal pathways associated with prostate cancer.
Liu Y; Song H; Pan J; Zhao J
J Appl Genet; 2014 Feb; 55(1):117-24. PubMed ID: 24154878
[TBL] [Abstract] [Full Text] [Related]
9. A reciprocal role of prostate cancer on stromal DNA damage.
Banerjee J; Mishra R; Li X; Jackson RS; Sharma A; Bhowmick NA
Oncogene; 2014 Oct; 33(41):4924-31. PubMed ID: 24141771
[TBL] [Abstract] [Full Text] [Related]
10. Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (tgfbr2) expression in prostate cancer.
Mishra S; Deng JJ; Gowda PS; Rao MK; Lin CL; Chen CL; Huang T; Sun LZ
Oncogene; 2014 Jul; 33(31):4097-106. PubMed ID: 24037531
[TBL] [Abstract] [Full Text] [Related]
11. Improvement of a predictive model of castration-resistant prostate cancer: functional genetic variants in TGFβ1 signaling pathway modulation.
Teixeira AL; Gomes M; Nogueira A; Azevedo AS; Assis J; Dias F; Santos JI; Lobo F; Morais A; Maurício J; Medeiros R
PLoS One; 2013; 8(8):e72419. PubMed ID: 23951322
[TBL] [Abstract] [Full Text] [Related]
12. Potential downstream target genes of aberrant ETS transcription factors are differentially affected in Ewing's sarcoma and prostate carcinoma.
Camões MJ; Paulo P; Ribeiro FR; Barros-Silva JD; Almeida M; Costa VL; Cerveira N; Skotheim RI; Lothe RA; Henrique R; Jerónimo C; Teixeira MR
PLoS One; 2012; 7(11):e49819. PubMed ID: 23185447
[TBL] [Abstract] [Full Text] [Related]
13. Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer.
Jackson RS; Placzek W; Fernandez A; Ziaee S; Chu CY; Wei J; Stebbins J; Kitada S; Fritz G; Reed JC; Chung LW; Pellecchia M; Bhowmick NA
Neoplasia; 2012 Jul; 14(7):656-65. PubMed ID: 22904682
[TBL] [Abstract] [Full Text] [Related]
14. Transcriptional regulatory networks in human lung adenocarcinoma.
Meng X; Lu P; Bai H; Xiao P; Fan Q
Mol Med Rep; 2012 Nov; 6(5):961-6. PubMed ID: 22895549
[TBL] [Abstract] [Full Text] [Related]
15. Loss of TGF-β responsiveness in prostate stromal cells alters chemokine levels and facilitates the development of mixed osteoblastic/osteolytic bone lesions.
Li X; Sterling JA; Fan KH; Vessella RL; Shyr Y; Hayward SW; Matrisian LM; Bhowmick NA
Mol Cancer Res; 2012 Apr; 10(4):494-503. PubMed ID: 22290877
[TBL] [Abstract] [Full Text] [Related]
16. Bone marrow derived mesenchymal stem cells incorporate into the prostate during regrowth.
Placencio VR; Li X; Sherrill TP; Fritz G; Bhowmick NA
PLoS One; 2010 Sep; 5(9):e12920. PubMed ID: 20886110
[TBL] [Abstract] [Full Text] [Related]
17. Epithelial Hic-5/ARA55 expression contributes to prostate tumorigenesis and castrate responsiveness.
Li X; Martinez-Ferrer M; Botta V; Uwamariya C; Banerjee J; Bhowmick NA
Oncogene; 2011 Jan; 30(2):167-77. PubMed ID: 20818421
[TBL] [Abstract] [Full Text] [Related]
18. prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis.
Li X; Placencio V; Iturregui JM; Uwamariya C; Sharif-Afshar AR; Koyama T; Hayward SW; Bhowmick NA
Oncogene; 2008 Nov; 27(56):7118-30. PubMed ID: 18724388
[TBL] [Abstract] [Full Text] [Related]
19. Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity.
Placencio VR; Sharif-Afshar AR; Li X; Huang H; Uwamariya C; Neilson EG; Shen MM; Matusik RJ; Hayward SW; Bhowmick NA
Cancer Res; 2008 Jun; 68(12):4709-18. PubMed ID: 18559517
[TBL] [Abstract] [Full Text] [Related]
20. Methylation silencing of transforming growth factor-beta receptor type II in rat prostate cancers.
Yamashita S; Takahashi S; McDonell N; Watanabe N; Niwa T; Hosoya K; Tsujino Y; Shirai T; Ushijima T
Cancer Res; 2008 Apr; 68(7):2112-21. PubMed ID: 18381416
[TBL] [Abstract] [Full Text] [Related]
[Next]
